HRP20020892B1 - 8c-hydrocarbyl-substituted estratrienes for use as selective estrogens - Google Patents
8c-hydrocarbyl-substituted estratrienes for use as selective estrogensInfo
- Publication number
- HRP20020892B1 HRP20020892B1 HR20020892A HRP20020892A HRP20020892B1 HR P20020892 B1 HRP20020892 B1 HR P20020892B1 HR 20020892 A HR20020892 A HR 20020892A HR P20020892 A HRP20020892 A HR P20020892A HR P20020892 B1 HRP20020892 B1 HR P20020892B1
- Authority
- HR
- Croatia
- Prior art keywords
- radical
- hydrogen atom
- group
- additional bond
- carbon atoms
- Prior art date
Links
- 150000002164 estratrienes Chemical class 0.000 title 1
- 229940011871 estrogen Drugs 0.000 title 1
- 239000000262 estrogen Substances 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 14
- -1 C1-C5-alkyl radical Chemical class 0.000 abstract 9
- 125000004432 carbon atom Chemical group C* 0.000 abstract 6
- 150000003254 radicals Chemical class 0.000 abstract 5
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 229920006395 saturated elastomer Polymers 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 229930195734 saturated hydrocarbon Natural products 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 abstract 2
- CPEONABTMRSIKA-UHFFFAOYSA-N 1,4$l^{2}-oxazinane Chemical compound C1COCC[N]1 CPEONABTMRSIKA-UHFFFAOYSA-N 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- PQGAHNJECSVDEI-UHFFFAOYSA-N [CH2]CCCCC Chemical compound [CH2]CCCCC PQGAHNJECSVDEI-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 150000002154 estra-1,3,5(10)-trienes Chemical class 0.000 abstract 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 abstract 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 abstract 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0062—Estrane derivatives substituted in position 17 alfa not substituted in position 17 beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0074—Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Pregnancy & Childbirth (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10019167A DE10019167A1 (de) | 2000-04-12 | 2000-04-12 | Substituierte Estratriene als selektiv wirksame Estrogene |
| US20737000P | 2000-05-26 | 2000-05-26 | |
| PCT/EP2001/004290 WO2001077139A1 (de) | 2000-04-12 | 2001-04-12 | 8.beta.-hydrocarbyl-substituierte estratriene als selektiv wirksame estrogene |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20020892A2 HRP20020892A2 (en) | 2005-02-28 |
| HRP20020892B1 true HRP20020892B1 (en) | 2011-08-31 |
Family
ID=26005365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20020892A HRP20020892B1 (en) | 2000-04-12 | 2002-11-11 | 8c-hydrocarbyl-substituted estratrienes for use as selective estrogens |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20040029847A1 (es) |
| EP (2) | EP1272505B1 (es) |
| JP (2) | JP3828423B2 (es) |
| CN (1) | CN100453549C (es) |
| AT (2) | ATE302790T1 (es) |
| AU (3) | AU2001273945A1 (es) |
| BG (1) | BG107173A (es) |
| BR (1) | BR0109983A (es) |
| CA (1) | CA2406177C (es) |
| CZ (1) | CZ20023382A3 (es) |
| DE (1) | DE50112561D1 (es) |
| DK (2) | DK1272504T3 (es) |
| EA (1) | EA006299B1 (es) |
| EE (1) | EE200200589A (es) |
| ES (2) | ES2245694T3 (es) |
| HK (1) | HK1057219A1 (es) |
| HR (1) | HRP20020892B1 (es) |
| HU (1) | HUP0300335A2 (es) |
| IL (2) | IL152248A0 (es) |
| MX (1) | MXPA02010066A (es) |
| NO (2) | NO325337B1 (es) |
| NZ (1) | NZ543724A (es) |
| PL (1) | PL207488B1 (es) |
| PT (1) | PT1272504E (es) |
| SK (1) | SK14632002A3 (es) |
| WO (2) | WO2001077139A1 (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0300335A2 (hu) * | 2000-04-12 | 2003-07-28 | Schering Ag. | 8béta-hidrokarbil-szubsztituált ösztratriének mint szelektív hatású ösztrogének, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények |
| DE10027887A1 (de) | 2000-05-31 | 2001-12-13 | Jenapharm Gmbh | Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| DE10039199A1 (de) * | 2000-08-10 | 2002-02-21 | Schering Ag | Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen |
| GB0020498D0 (en) * | 2000-08-18 | 2000-10-11 | Sterix Ltd | Compound |
| DE10151363A1 (de) * | 2001-10-17 | 2003-05-08 | Schering Ag | Somatotrope Therapie |
| DE10226326A1 (de) * | 2002-06-11 | 2004-01-15 | Schering Ag | 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene |
| EP1468690B1 (en) * | 2003-03-27 | 2008-10-08 | Pantarhei Bioscience B.V. | Use of estrogens for the treatment of infertility in male mammals |
| DE10318896A1 (de) | 2003-04-22 | 2004-11-25 | Schering Ag | 8beta-Vinyl-11beta-(omega-substituierte)alkyl-estra-1,3,5(10)-triene |
| PT1689410E (pt) * | 2003-11-26 | 2008-08-18 | Bayer Schering Pharma Ag | Prevenção e tratamento de doenças cardíacas hipertensivas pelos estrogénios selectivos 8beta-vinil-estra-1,3,5(10)-trieno-3,17beta-diol e 17beta-fluoro-9alfa-vinil-estra-1,3,5(10)-trieno-3,16alfa-diol |
| US7534780B2 (en) | 2004-05-21 | 2009-05-19 | Bayer Schering Pharma Aktiengesellschaft | Estradiol prodrugs |
| DE102005057224A1 (de) * | 2005-11-29 | 2007-05-31 | Bayer Schering Pharma Ag | Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| DE102005057225A1 (de) * | 2005-11-29 | 2007-05-31 | Bayer Schering Pharma Ag | Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| EP2014672A1 (en) * | 2007-07-12 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | 8-beta-substituted estratrienes as selectively active estrogens |
| CN101945646A (zh) * | 2008-02-13 | 2011-01-12 | 拜耳先灵医药股份有限公司 | 含雌二醇的药物递送系统 |
| AU2009214307A1 (en) * | 2008-02-13 | 2009-08-20 | Bayer Intellectual Property Gmbh | Drug delivery system with stabilising effect |
| EP2143432A1 (en) * | 2008-07-11 | 2010-01-13 | Bayer Schering Pharma AG | 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer |
| JP2012509286A (ja) * | 2008-11-21 | 2012-04-19 | バイエル ファーマ アクチエンゲゼルシャフト | 薬物送達システム |
| ES2885523T3 (es) | 2011-11-23 | 2021-12-14 | Therapeuticsmd Inc | Formulaciones y terapias de reposición hormonal de combinación naturales |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3681407A (en) * | 1969-06-18 | 1972-08-01 | American Cyanamid Co | 3-methoxy 8{62 -methylestra 1,3,5(10),9(11)-tetraene-17{62 -carboxylic acid lower alkyl ester and intermediates in the preparation thereof |
| US3736345A (en) * | 1971-05-18 | 1973-05-29 | American Cyanamid Co | Steroid-like compounds and method of synthesis |
| US3806546A (en) * | 1969-06-18 | 1974-04-23 | American Cyanamid Co | Steroid-like compounds and method of synthesis |
| US4961931A (en) * | 1982-07-29 | 1990-10-09 | Alza Corporation | Method for the management of hyperplasia |
| DE4018828A1 (de) * | 1989-06-08 | 1990-12-13 | Schering Ag | Verfahren zur herstellung c7-(alpha)-substituierter 8(alpha)- und 8ss-estra-1,3,5(10)-triene und c8-(alpha)-substituierter estra-1,3,5(10)-triene sowie neue zwischenprodukte fuer dieses verfahren |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2743E (fr) * | 1902-01-11 | 1904-12-15 | Adolphe Ernest Pointe | Panification augmentant le rendement et la digestibilité |
| JPS454059Y1 (es) * | 1967-11-04 | 1970-02-25 | ||
| JPS454060Y1 (es) * | 1967-12-11 | 1970-02-25 | ||
| US3501530A (en) * | 1968-02-27 | 1970-03-17 | American Cyanamid Co | Substituted naphthalenones,naphthalenediones and d-homo - beta - nor estra-1,3,5(10),9(11)-tetraenes |
| US3709878A (en) * | 1970-07-20 | 1973-01-09 | Sandoz Ag | 8 alpha-methyl-substituted-steroids |
| CA2668824A1 (en) * | 1996-05-01 | 1997-11-06 | The Government Of The United States Of America, Represented By The Secre Tary Of The Department Of Health And Human Services | 21-substituted progesterone derivatives as new antiprogestational agents |
| ATE222922T1 (de) * | 1998-11-20 | 2002-09-15 | Akzo Nobel Nv | Estrogenische estra-1,3,5(10)-trien verbindungen mit verschiedenen wirkungen auf estrogenrezeptor alpha und beta mit einer unverzweigten kohlenwasserstoffkette von 5-9 kohlenstoffatomen in position 11 |
| HUP0300335A2 (hu) * | 2000-04-12 | 2003-07-28 | Schering Ag. | 8béta-hidrokarbil-szubsztituált ösztratriének mint szelektív hatású ösztrogének, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények |
| DE10019167A1 (de) * | 2000-04-12 | 2001-10-18 | Schering Ag | Substituierte Estratriene als selektiv wirksame Estrogene |
| DE10318896A1 (de) * | 2003-04-22 | 2004-11-25 | Schering Ag | 8beta-Vinyl-11beta-(omega-substituierte)alkyl-estra-1,3,5(10)-triene |
-
2001
- 2001-04-12 HU HU0300335A patent/HUP0300335A2/hu unknown
- 2001-04-12 US US10/257,287 patent/US20040029847A1/en not_active Abandoned
- 2001-04-12 EA EA200201052A patent/EA006299B1/ru not_active IP Right Cessation
- 2001-04-12 CN CNB018107745A patent/CN100453549C/zh not_active Expired - Fee Related
- 2001-04-12 AU AU2001273945A patent/AU2001273945A1/en not_active Abandoned
- 2001-04-12 WO PCT/EP2001/004290 patent/WO2001077139A1/de active IP Right Grant
- 2001-04-12 EE EEP200200589A patent/EE200200589A/xx unknown
- 2001-04-12 ES ES01940331T patent/ES2245694T3/es not_active Expired - Lifetime
- 2001-04-12 AT AT01940331T patent/ATE302790T1/de not_active IP Right Cessation
- 2001-04-12 DE DE50112561T patent/DE50112561D1/de not_active Expired - Lifetime
- 2001-04-12 JP JP2001575608A patent/JP3828423B2/ja not_active Expired - Lifetime
- 2001-04-12 SK SK1463-2002A patent/SK14632002A3/sk unknown
- 2001-04-12 ES ES01931609T patent/ES2287127T3/es not_active Expired - Lifetime
- 2001-04-12 EP EP01940331A patent/EP1272505B1/de not_active Expired - Lifetime
- 2001-04-12 US US10/257,288 patent/US7378404B2/en not_active Expired - Fee Related
- 2001-04-12 PL PL358667A patent/PL207488B1/pl not_active IP Right Cessation
- 2001-04-12 WO PCT/EP2001/004289 patent/WO2001077138A1/de active IP Right Grant
- 2001-04-12 NZ NZ543724A patent/NZ543724A/en unknown
- 2001-04-12 MX MXPA02010066A patent/MXPA02010066A/es active IP Right Grant
- 2001-04-12 IL IL15224801A patent/IL152248A0/xx active IP Right Grant
- 2001-04-12 CA CA2406177A patent/CA2406177C/en not_active Expired - Fee Related
- 2001-04-12 CZ CZ20023382A patent/CZ20023382A3/cs unknown
- 2001-04-12 AT AT01931609T patent/ATE363487T1/de active
- 2001-04-12 AU AU2001258341A patent/AU2001258341B2/en not_active Ceased
- 2001-04-12 AU AU5834101A patent/AU5834101A/xx active Pending
- 2001-04-12 PT PT01931609T patent/PT1272504E/pt unknown
- 2001-04-12 BR BR0109983-3A patent/BR0109983A/pt not_active IP Right Cessation
- 2001-04-12 DK DK01931609T patent/DK1272504T3/da active
- 2001-04-12 DK DK01940331T patent/DK1272505T3/da active
- 2001-04-12 EP EP01931609A patent/EP1272504B1/de not_active Expired - Lifetime
-
2002
- 2002-10-08 BG BG107173A patent/BG107173A/bg unknown
- 2002-10-10 IL IL152248A patent/IL152248A/en not_active IP Right Cessation
- 2002-10-11 NO NO20024908A patent/NO325337B1/no unknown
- 2002-10-11 NO NO20024907A patent/NO20024907L/no not_active Application Discontinuation
- 2002-11-11 HR HR20020892A patent/HRP20020892B1/xx not_active IP Right Cessation
-
2004
- 2004-01-09 HK HK04100140.5A patent/HK1057219A1/xx not_active IP Right Cessation
-
2008
- 2008-03-11 US US12/045,979 patent/US20080182829A1/en not_active Abandoned
- 2008-06-25 JP JP2008166585A patent/JP2008280355A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3681407A (en) * | 1969-06-18 | 1972-08-01 | American Cyanamid Co | 3-methoxy 8{62 -methylestra 1,3,5(10),9(11)-tetraene-17{62 -carboxylic acid lower alkyl ester and intermediates in the preparation thereof |
| US3806546A (en) * | 1969-06-18 | 1974-04-23 | American Cyanamid Co | Steroid-like compounds and method of synthesis |
| US3736345A (en) * | 1971-05-18 | 1973-05-29 | American Cyanamid Co | Steroid-like compounds and method of synthesis |
| US4961931A (en) * | 1982-07-29 | 1990-10-09 | Alza Corporation | Method for the management of hyperplasia |
| DE4018828A1 (de) * | 1989-06-08 | 1990-12-13 | Schering Ag | Verfahren zur herstellung c7-(alpha)-substituierter 8(alpha)- und 8ss-estra-1,3,5(10)-triene und c8-(alpha)-substituierter estra-1,3,5(10)-triene sowie neue zwischenprodukte fuer dieses verfahren |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20020892B1 (en) | 8c-hydrocarbyl-substituted estratrienes for use as selective estrogens | |
| NZ507735A (en) | Indole derivatives useful for treating malignant and other diseases caused by pathological cell proliferation | |
| HUP9900684A2 (hu) | Új 19-nor-pregnén-származékok | |
| BR0307687A (pt) | Composições cosméticas tópicas | |
| BG103903A (en) | Nonsteroid (hetero) cyclic substituted acylanylides of mixed gestagenous and androgenous activity | |
| MXPA04006340A (es) | Estabilizacion de bloqueadores solares en composiciones cosmeticas. | |
| GR3034562T3 (en) | 21-substituted progesterone derivatives as new antiprogestational agents | |
| DE69104011T2 (de) | Anhydride kosmetische Zusammensetzung als Aerosolschaum. | |
| TW200728915A (en) | A salt suitable for an acid generator and a chemically amplified resist composition containing the same | |
| HRP20020317B1 (en) | Pharmaceutically active compounds | |
| CY1105957T1 (el) | Χρηση οιστρογονων ενωσεων σε συνδυασμο με ενωσεις προγεστογονου (progestogen) σε θepαπεια ορμονικης αντικαταστασης | |
| BG101190A (en) | Pharmaceutical preparation containing estra-1,3,5/10/-triene derivatives | |
| BRPI0409831A (pt) | composição de condicionamento de tecidos, e, uso de um material não iÈnico | |
| NZ332990A (en) | oral pharmaceutical composition containing a H+, K+-atpase inhibitor having a extended blood plasma profile | |
| RS50010B (sr) | Derivati 5'-dezoksi-citidina | |
| ATE733T1 (de) | 2'-deoxy-5-fluorouridin-derivate, ein verfahren zu deren herstellung und sie enthaltende antitumor-zusammensetzungen. | |
| DE69902684T2 (de) | Estrogenische estra-1,3,5(10)-trien verbindungen mit verschiedenen wirkungen auf estrogenrezeptor alpha und beta mit einer unverzweigten kohlenwasserstoffkette von 5-9 kohlenstoffatomen in position 11 | |
| PL1758970T3 (pl) | Mieszanka zapachowa do bezwonnego paliwa gazowego | |
| DK0988312T3 (da) | 17beta-allyloxy(thio)alkyl-androstanderivater til modulering af meiose | |
| RS49739B (sr) | Kompleks platine, njegovo dobijanje i terapeutska primena | |
| MX2009005782A (es) | Derivados de pirano, procedimiento de preparacion y uso de los mismos en perfumeria y saborizantes. | |
| TR200003142T2 (tr) | Yeni oktahidro-6,10-diokso-6H-piridazino [1,2-A] [1,2] diazepin-1-karboksilik asit türevleri. | |
| NO20025392L (no) | 2-substituerte pregna-1,3-5(10)-trien og chola-1,3,5(10)- trienderivater ogderes biologiske aktivitet | |
| DE60013618D1 (de) | Polyalkoxylierte superamide und ihre verwendung als emulgiermittel | |
| ES383723A1 (es) | Procedimiento para la obtencion de 17 alfa-alquil-11-beta- 13-beta-dialquilgona-1, 3, 5 (10)-trieno-3,17 beta-diol-3- cicloalquil eteres. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| PNAN | Change of the applicant name, address/residence |
Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE |
|
| PNAN | Change of the applicant name, address/residence |
Owner name: BAYER PHARMA AKTIENGESELLSCHAFT, DE |
|
| B1PR | Patent granted | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20120330 Year of fee payment: 12 |
|
| PPPP | Transfer of rights |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE |
|
| PBON | Lapse due to non-payment of renewal fee |
Effective date: 20130413 |